Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Amgen Inc.

Insiders have been trading these 5 stocks: (($AMGN)), (($CEG)), (($FSLY)), (($KEEL)) and (($BX)). Here is a breakdown of their recent trades and th...

Amgen, Constellation, Fastly, Keel & Blackstone Shock Wall St.

Amgen Inc ($AMGN) announced an update on their ongoing clinical study. Amgen Inc. (AMGN) is launching a new Phase 2/3 study called “A Trial of Ineb...

Amgen Targets Autoimmune Hepatitis With New Inebilizumab Trial

In a report released yesterday, Courtney Breen from Bernstein maintained a Hold rating on Amgen, with a price target of $345.00. The company’s shar...

Bernstein Reaffirms Their Hold Rating on Amgen (AMGN)

In a report released today, Michael Yee from UBS maintained a Buy rating on Amgen, with a price target of $440.00. Yee covers the Healthcare sector...

UBS Keeps Their Buy Rating on Amgen (AMGN)

In a report released today, Geoff Meacham from Citi maintained a Hold rating on Amgen, with a price target of $345.00. Meacham covers the Healthcar...

Citi Keeps Their Hold Rating on Amgen (AMGN)

TD Cowen analyst Yaron Werber reiterated a Buy rating on Amgen yesterday and set a price target of $452.00. According to TipRanks, Werber is a 5-st...

TD Cowen Sticks to Its Buy Rating for Amgen (AMGN)

Amgen Inc ($AMGN) announced an update on their ongoing clinical study. The Phase 3 MARITIME-1-EXTENSION study from Amgen Inc. looks at how well and...

Amgen Extends Obesity Trial, Sharpening Its Long-Term Weight-Loss Bet

Amgen Inc ($AMGN) announced an update on their ongoing clinical study. Amgen Inc. (AMGN) is running an early-stage study called “A Trial Evaluating...

Amgen’s AMG 127 Trial Signals a New Push Into Type 2 Diabetes

RBC Capital analyst Luca Issi maintained a Buy rating on Amgen on July 29 and set a price target of $370.00. The company’s shares closed yesterday ...

RBC Capital Remains a Buy on Amgen (AMGN)

Dividend ETFs are one of the most popular ways to earn passive income, but choosing the right fund isn’t always easy. Among the leading options are...

SCHD vs. VYMI: Which Dividend ETF Comes Out on Top?

Amgen Inc ($AMGN) announced an update on their ongoing clinical study. Amgen Inc. has ended a late-stage study of rocatinlimab in prurigo nodularis...

Amgen Halts Key Phase 3 Rocatinlimab Study, Resetting Expectations in Dermatology

Bernstein analyst Courtney Breen maintained a Hold rating on Amgen yesterday and set a price target of $335.00. The company’s shares closed yesterd...

Amgen Inc ($AMGN) announced an update on their ongoing clinical study. Amgen Inc. has stopped a late stage study testing bemarituzumab in advanced ...

Amgen Halts Bemarituzumab Gastric Cancer Trial, Shifting Oncology Expectations

Amgen Inc ($AMGN) announced an update on their ongoing clinical study. Amgen Inc. (AMGN) has completed a Phase 1 trial that tests how its obesity d...

Amgen Advances Obesity Pipeline With Fresh Data on AMG 133 Injection Formats

Amgen Inc ($AMGN) announced an update on their ongoing clinical study. Amgen Inc. has halted a key Phase 3 maintenance study known as ROCKET-ASCEND...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AMGN	$415.21	-0.63%	2.04M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	AMGN	$415.21	-0.6%	2.04M
3
4
5
6

AMGN

Get Amgen Inc. Data in Excel

Get Amgen Inc. Data in Excel